All sponsors

Verastem, Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS10
PHASE 3 / 2-31
RECRUITING5
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO50%

Delay Index: of 6 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +15.0 months). See all sponsors →

Open Verastem, Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
RAMP 201
NCT04625270
P2Active, not recruitingLow Grade Ovarian Serous Adenocarcinoma; Ovarian Cancer2252024-11-15 (+18 mo)
RAMP201J
NCT06682572
P2Active, not recruitingLow Grade Serous Ovarian Cancer; Ovarian Cancer162025-12
RAMP203
NCT05074810
P1/2Active, not recruitingNon Small Cell Lung Cancer; KRAS Activating Mutation1532026-06 (+30 mo)
RAMP205
NCT05669482
P1/2Active, not recruitingKRAS Activating Mutation; Metastatic Cancer402026-08-31 (+15 mo)
TARGET-D 203
NCT07659795
P2RecruitingColorectal Cancer1502027-06
TARGET-D 202
NCT07659782
P2RecruitingNon-Small Cell Lung Cancer1052027-06
VS-7375
NCT07644559
P2RecruitingPancreatic Ductal Adenocarcinoma (PDAC); G12D Mutated KRAS1852027-06
avutometinib + defactininb combination
NCT07747506
P2Not yet recruitingLow Grade Ovarian Serous Adenocarcinoma; Ovarian Cancer22027-08-01
RAMP 301
NCT06072781
P3RecruitingLow Grade Serous Ovarian Cancer2702028-10-15
VS-7375
NCT07020221
P1/2RecruitingPancreatic Ductal Adenocarcinoma; Non Small Cell Lung Cancer6162028-12 (+3 mo)